Eli Lilly launches Mounjaro in India for obesity & diabetes management

Eli Lilly and Company has launched Mounjaro in a single-dose vial, which has been authorized to be marketed by the Central Drugs Standard Control Organization (CDSCO). This first-ever treatment drug is designed to hit both these two receptors named cytokines GIP (glucose-insulinotropic polypeptide-like polypeptide) and GLP-1 (glucagon-like peptide-1) to optimize and bring about new ways to tackle different diseases including obesity, overweight conditions, and type 2 diabetes.

One can take Mounjaro along with a low-calorie diet and higher physical activity that will be helpful to control obesity in adults with a BMI of 30 kg/m² or higher (obesity) or 27 kg/m² or higher (overweight) with the condition of weight being one of them. It is, additionally, sanctioned for a better result of controlling diabetes when it is added to a diet and shows active results.

Winselow Tucker, president and general manager, Lilly India said, "The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases".

He added, "Our mission to making life better for people living with obesity and diabetes in India is reflected in our efforts to accelerate the introduction of innovative medicines. The launch of Mounjaro demonstrates our ongoing support to this mission and our shared vision of a healthier nation".

Tirzepatide, the active ingredient, went through rigorous testing in global clinical trials, including the SURMOUNT-1 trials for weight management and the SURPASS trials for diabetes. Mounjaro, the medicament to be used once a week, supports insulin secretion and as such decreases glucagon levels and insulin resistance.

It stimulates the subfornical organ, thus, to restrict the hunger feeling and increase the satiety through the GIP and GLP-1 receptors that are located in the brain leading to fewer food intakes, fat burning, and fat metabolism improvement. The concern of the business in relation to Mounjaro's positive influence on millions of such people is clear.